Diabetes and pancreatic cancer: Chicken or egg?

Pancreas

Volumn 40, Issue 3, 2011, Pages 339-351

  Magruder, J Trent ^a   Elahi, Dariush ^a   Andersen, Dana K ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

diabetes; hyperinsulinemia; metformin; pancreatic cancer; pancreatic polypeptide (PP); type 3 diabetes mellitus (T3DM)

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; BIOLOGICAL MARKER; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE; INSULIN; INSULIN DERIVATIVE; MEGLITINIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; BARIATRIC SURGERY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CELL PROLIFERATION; CLINICAL EXAMINATION; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE ASSOCIATION; DRUG EFFICACY; EPIDEMIOLOGICAL DATA; EVIDENCE BASED PRACTICE; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HISTOPATHOLOGY; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LABORATORY TEST; MORBID OBESITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS CANCER; PANCREAS CARCINOMA; PANCREATITIS; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RISK REDUCTION; TYPE 3 DIABETES MELLITUS;

CASE-CONTROL STUDIES; CAUSALITY; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE; HUMANS; ISLET AMYLOID POLYPEPTIDE; MALE; METFORMIN; PANCREATIC NEOPLASMS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 79953901413     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e318209e05d     Document Type: Review

References (122)

1. Bright R. Cases and observations connected with disease of the pancreas and duodenum. Med Chir Trans. 1833;18:1-56.
2. Marble A. Diabetes and cancer. N Engl J Med. 1934;211:339-349.
3. Grauer FW. Pancreatic carcinoma: a review of thirty-four autopsies. Arch Intern Med. 1939;63:884-889.
4. Green RC Jr, Baggenstoss AH, Sprague RG. Diabetes mellitus in association with primary carcinoma of the pancreas. Diabetes. 1958;7(4):308-311.
5. Pannala R, Leirness JB, Bamlet WR, et al. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology. 2008;134(4):981-987. (Pubitemid 351451984)
6. Diabetes Overview. Available at: http://diabetes.niddk.nih.gov/dm/pubs/ overview/. Accessed December 31, 2009.
7. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57(1):43-66.
8. Smith GD, Egger M, Shipley MJ, et al. Post-challenge glucose concentration, impaired glucose tolerance, diabetes, and cancer mortality in men. Am J Epidemiol. 1992;136(9):1110-1114. (Pubitemid 23005170)
9. Gullo L, Pezzilli R, Morselli-Labate AM, et al. Diabetes and the risk of pancreatic cancer. N Engl J Med. 1994;331(2):81-84. (Pubitemid 24202222)
10. Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA. 1995;273(20):1605-1609.
11. Wynder EL, Mabuchi K, Maruchi N, et al. Epidemiology of cancer of the pancreas. J Natl Cancer Inst. 1973;50(3):645-667.
12. Lin RS, Kessler II. A multifactorial model for pancreatic cancer in man. Epidemiologic evidence. JAMA. 1981;245(2):147-152.
13. Gold EB, Gordis L, Diener MD, et al. Diet and other risk factors for cancer of the pancreas. Cancer. 1985;55(2):460-467. (Pubitemid 15152824)
14. Norell S, Ahlbom A, Erwald R, et al. Diabetes, gall stone disease, and pancreatic cancer. Br J Cancer. 1986;54(2):377-378.
15. Cuzick J, Babiker AG. Pancreatic cancer, alcohol, diabetes mellitus and gall-bladder disease. Int J Cancer. 1989;43(3):415-421. (Pubitemid 19092322)
16. Farrow DC, Davis S. Risk of pancreatic cancer in relation to medical history and the use of tobacco, alcohol and coffee. Int J Cancer. 1990;45(5):816-820. (Pubitemid 20179628)
17. Jain M, Howe GR, St Louis P, et al. Coffee and alcohol as determinants of risk of pancreas cancer: a case-control study from Toronto. Int J Cancer. 1991;47(3):384-389.
18. Bueno de Mesquita HB, Maisonneuve P, Moerman CJ, et al. Aspects of medical history and exocrine carcinoma of the pancreas: a population-based case-control study in The Netherlands. Int J Cancer. 1992;52(1):17-23.
19. Kalapothaki V, Tzonou A, Hsieh CC, et al. Tobacco, ethanol, coffee, pancreatitis, diabetes mellitus, and cholelithiasis as risk factors for pancreatic carcinoma. Cancer Causes Control. 1993;4(4):375-382. (Pubitemid 23205749)
20. Ragozzino M, Melton LJ 3rd, Chu CP, et al. Subsequent cancer risk in the incidence cohort of Rochester, Minnesota, residents with diabetes mellitus. J Chronic Dis. 1982;35(1):13-19. (Pubitemid 12213476)
21. Whittemore AS, Paffenbarger RS Jr, Anderson K, et al. Early precursors of pancreatic cancer in college men. J Chronic Dis. 1983;36(3):251-256. (Pubitemid 13160594)
22. Hiatt RA, Klatsky AL, Armstrong MA. Pancreatic cancer, blood glucose and beverage consumption. Int J Cancer. 1988;41(6):794-797.
23. Mills PK, Beeson WL, Abbey DE, et al. Dietary habits and past medical history as related to fatal pancreas cancer risk among Adventists. Cancer. 1988;61(12):2578-2585.
24. Balkau B, Barrett-Connor E, Eschwege E, et al. Diabetes and pancreatic carcinoma. Diabetes Metab. 1993;19(5):458-462. (Pubitemid 24039448)
25. Friedman GD, van den Eeden SK. Risk factors for pancreatic cancer: an exploratory study. Int J Epidemiol. 1993;22(1):30-37. (Pubitemid 23083951)
26. Adami HO, McLaughlin J, Ekbom A, et al. Cancer risk in patients with diabetes mellitus. Cancer Causes Control. 1991;2(5):307-314.
27. Shibata A, Mack TM, Paganini-Hill A, et al. A prospective study of pancreatic cancer in the elderly. Int J Cancer. 1994;58(1):46-49. (Pubitemid 24213968)
28. Chow WH, Gridley G, Nyren O, et al. Risk of pancreatic cancer following diabetes mellitus: a nationwide cohort study in Sweden. J Natl Cancer Inst. 1995;87(12):930-931.
29. Calle EE, Murphy TK, Rodriguez C, et al. Diabetes mellitus and pancreatic cancer mortality in a prospective cohort of United States adults. Cancer Causes Control. 1998;9(4):403-410. (Pubitemid 28466692)
30. Wideroff L, Gridley G, Mellemkjaer L, et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst. 1997;89(18):1360-1365. (Pubitemid 27418027)
31. Gapstur SM, Gann PH, Lowe W, et al. Abnormal glucose metabolism and pancreatic cancer mortality. JAMA. 2000;283(19):2552-2558. (Pubitemid 30324198)
32. Silverman DT. Risk factors for pancreatic cancer: a case-control study based on direct interviews. Teratogenesis, Carcinogenis, and Mutagenesis. 2001;21(1):7-25.
33. Michaud DS, Giovannucci E, Willett WC, et al. Physical activity, obesity, height, and the risk of pancreatic cancer. JAMA. 2001;286(8):921-929. (Pubitemid 33010338)
34. Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625-1638. (Pubitemid 36459468)
35. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, et al. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer. 2005;92(11):2076-2083. (Pubitemid 40897433)
36. O'Mara BA, Byers T, Schoenfeld E. Diabetes mellitus and cancer risk: a multisite case-control study. J Chronic Dis. 1985;38(5):435-441. (Pubitemid 15025864)
37. Ekoe JM, Ghadirian P, Simard A, et al. Diabetes mellitus and pancreatic cancer: a case-control study in greater Montreal, Quebec, Canada. Rev Epidemiol Sante Publique. 1992;40(6):447-453. (Pubitemid 23061084)
38. Lee CT, Chang FY, Lee SD. Risk factors for pancreatic cancer in orientals. J Gastroenterol Hepatol. 1996;11(5):491-495.
39. Frye JN, Inder WJ, Dobbs BR, et al. Pancreatic cancer and diabetes: is there a relationship? A case-controlled study. Aust N Z J Surg. 2000;70(10):722-724.
40. Bonelli L, Aste H, Bovo P, et al. Exocrine pancreatic cancer, cigarette smoking, and diabetes mellitus: a case-control study in northern Italy. Pancreas. 2003;27(2):143-149. (Pubitemid 36950726)
41. Lund Nilsen TI, Johnsen R, Vatten LJ. Socio-economic and lifestyle factors associated with the risk of prostate cancer. Br J Cancer. 2000;82(7):1358-1363. (Pubitemid 30145359)
42. Lin Y, Tamakoshi A, Kawamura T, et al. Risk of pancreatic cancer in relation to alcohol drinking, coffee consumption and medical history: findings from the Japan collaborative cohort study for evaluation of cancer risk. Int J Cancer. 2002;99(5):742-746. (Pubitemid 34538756)
43. Stolzenberg-Solomon RZ, Pietinen P, Taylor PR, et al. Prospective study of diet and pancreatic cancer in male smokers. Am J Epidemiol. 2002;155(9):783-792. (Pubitemid 34456987)
44. Inoue M, Tajima K, Takezaki T, et al. Epidemiology of pancreatic cancer in Japan: a nested case-control study from the Hospital-based Epidemiologic Research Program at Aichi Cancer Center (HERPACC). Int J Epidemiol. 2003;32(2):257-262. (Pubitemid 36622272)
45. Rulyak SJ, Lowenfels AB, Maisonneuve P, et al. Risk factors for the development of pancreatic cancer in familial pancreatic cancer kindreds. Gastroenterology. 2003;124(5):1292-1299. (Pubitemid 36531804)
46. Batty GD, Shipley MJ, Marmot M, et al. Diabetes status and post-load plasma glucose concentration in relation to site-specific cancer mortality: findings from the original Whitehall study. Cancer Causes Control. 2004;15(9):873-881. (Pubitemid 39663863)
47. Coughlin SS, Calle EE, Teras LR, et al. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol. 2004;159(12):1160-1167. (Pubitemid 38747263)
48. Jee SH, Ohrr H, Sull JW, et al. Fasting serum glucose level and cancer risk in Korean men and women. JAMA. 2005;293(2):194-202. (Pubitemid 40095870)
49. Harris MI, Hadden WC, Knowler WC, et al. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20-74 yr. Diabetes. 1987;36(4):523-534. (Pubitemid 18023199)
50. Selvin E, Coresh J, Brancati FL. The burden and treatment of diabetes in elderly individuals in the U.S. Diabetes Care. 2006;29(11):2415-2419. (Pubitemid 44912245)
51. Chari ST, Leibson CL, Rabe KG, et al. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology. 2005;129(2):504-511. (Pubitemid 41096638)
52. Danaei G, Friedman AB, Oza S, et al. Diabetes prevalence and diagnosis in US states: analysis of health surveys. Population Health Metrics. 2009;7:16.
53. Bakalar N. Diabetes: a state-by-state breakdown. The New York Times. 10/13/2009:6. Available at: http://www.nytimes.com/2009/10/13/health/13stat. html. Accessed January 26, 2010.
54. ACS: Statistics for 2008. Available at: http://www.cancer.org/docroot/ STT/stt-0-2008.asp?sitearea=STT&level=1. Accessed December 31, 2009.
55. U.S. Census Bureau. Population Estimates. Available at: http://www.census.gov/popest/states/. Accessed December 31, 2009.
56. Pickle LW, Hao Y, Jemal A, et al. A new method of estimating United States and state-level cancer incidence counts for the current calendar year. CA Cancer J Clin. 2007;57(1):30-42. (Pubitemid 46148090)
57. Inoue M, Iwasaki M, Otani T, et al. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med. 2006;166(17):1871-1877. (Pubitemid 44455170)
58. Saydah SH, Platz EA, Rifai N, et al. Association of markers of insulin and glucose control with subsequent colorectal cancer risk. Cancer Epidemiol Biomarker Prevent. 2003;12:412-418. (Pubitemid 36578478)
59. Stolzenberg-Solomon RZ, Graubard BI, Chari S, et al. Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA. 2005;294(22):2872-2878. (Pubitemid 41785868)
60. Butler AE, Galasso R, Matveyenko A, et al. Pancreatic duct replication is increased with obesity and type 2 diabetes in humans. Diabetologia. 2010;53(1):21-26.
61. Christou NV, Lieberman M, Sampalis F, et al. Bariatric surgery reduces cancer risk in morbidly obese patients. Surg Obes Relat Dis. 2008;4(6):691-695.
62. Adams TD, Stroup AM, Gress RE, et al. Cancer incidence and mortality after gastric bypass surgery. Obesity (Silver Spring). 2009;17(4):796-802.
63. Sjostrom L, Narbro K, Sjostrom CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357(8):741-752. (Pubitemid 47295641)
64. Ding XZ, Fehsenfeld DM, Murphy LO, et al. Physiological concentrations of insulin augment pancreatic cancer cell proliferation and glucose utilization by activating MAP kinase, PI3 kinase and enhancing GLUT-1 expression. Pancreas. 2000;21(3):310-320.
65. Maisonneuve P, Lowenfels AB, Bueno-de-Mesquita HB, et al. Past medical history and pancreatic cancer risk: results from a multicenter case-control study. Ann Epidemiol. 2010;20(2):92-98.
66. Berstein LM. Clinical usage of hypolipidemic and antidiabetic drugs in the prevention and treatment of cancer. Cancer Lett. 2005;224(2):203-212. (Pubitemid 40731528)
67. Evans JM, Donnelly LA, Emslie-Smith AM, et al. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005;330(7503):1304-1305. (Pubitemid 40813563)
68. Libby G, Donnelly LA, Donnan PT, et al. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care. 2009;32(9):1620-1625.
69. Bowker SL, Majumdar SR, Veugelers P, et al. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006;29(2):254-258. (Pubitemid 44106500)
70. Belfiore A. The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr Pharm Des. 2007;13(7):671-686. (Pubitemid 46510744)
71. Matveyenko AV, Dry S, Cox HI, et al. Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin. Diabetes. 2009;58(7):1604-1615.
72. Schneider MB, Matsuzaki H, Haorah J, et al. Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology. 2001;120(5):1263-1270. (Pubitemid 32246678)
73. Li D, Yeung SC, Hassan MM, et al. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology. 2009;137(2):482-488.
74. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008;8(12):915-928.
75. Rozengurt E, Sinnett-Smith J, Kisfalvi K. Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer. Clin Cancer Res. 2010;16(9):2505-2511.
76. Shaw RJ, Lamia KA, Vasquez D, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 2005;310(5754):1642-1646. (Pubitemid 41780780)
77. Zakikhani M, Dowling R, Fantus IG, et al. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 2006;66(21):10269-10273. (Pubitemid 44799743)
78. Kisfalvi K, Eibl G, Sinnett-Smith J, et al. Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res. 2009;69(16):6539-6545.
79. Shaw RJ, Bardeesy N, Manning BD, et al. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell. 2004;6(1):91-99. (Pubitemid 38903165)
80. Alessi DR, Sakamoto K, Bayascas JR. LKB1-dependent signaling pathways. Annu Rev Biochem. 2006;75:137-163. (Pubitemid 44118029)
81. Rozengurt E. Mitogenic signaling pathways induced by G protein-coupled receptors. J Cell Physiol. 2007;213(3):589-602. (Pubitemid 350058250)
82. Dowling RJ, Zakikhani M, Fantus IG, et al. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 2007;67(22):10804-10812. (Pubitemid 350145909)
83. Gotlieb WH, Saumet J, Beauchamp MC, et al. In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol. 2008;110(2):246-250.
84. Jiralerspong S, Palla SL, Giordano SH, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol. 2009;27(20):3297-3302.
85. Chari ST, Leibson CL, Rabe KG, et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology. 2008;134(1):95-101. (Pubitemid 350309328)
86. McPhee JT, Hill JS, Whalen GF, et al. Perioperative mortality for pancreatectomy: a national perspective. Ann Surg. 2007;246(2):246-253. (Pubitemid 47196522)
87. Gudjonsson B. Cancer of the pancreas. 50 years of surgery. Cancer. 1987;60(9):2284-2303.
88. Landis SH, Murray T, Bolden S, et al. Cancer statistics, 1999. CA Cancer J Clin. 1999;49(1):8-31, 1.
89. Pelaez-Luna M, Takahashi N, Fletcher JG, et al. Resectability of presymptomatic pancreatic cancer and its relationship to onset of diabetes: a retrospective review of CT scans and fasting glucose values prior to diagnosis. Am J Gastroenterol. 2007;102(10):2157-2163. (Pubitemid 47493852)
90. Ogawa Y, Tanaka M, Inoue K, et al. A prospective pancreatographic study of the prevalence of pancreatic carcinoma in patients with diabetes mellitus. Cancer. 2002;94(9):2344-2349. (Pubitemid 34457114)
91. Damiano J, Bordier L, Le Berre JP, et al. Should pancreas imaging be recommended in patients over 50 years when diabetes is discovered because of acute symptoms? Diabetes Metab. 2004;30(2):203-207.
92. Brentnall TA, Bronner MP, Byrd DR, et al. Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med. 1999;131(4):247-255. (Pubitemid 29383653)
93. Pannala R, Basu A, Petersen GM, et al. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol. 2009;10(1):88-95.
94. Bartosch-Harlid A, Andersson R. Diabetes mellitus in pancreatic cancer and the need for diagnosis of asymptomatic disease. Pancreatology. 2010;10(4):423-428.
95. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74-108.
96. Gangi S, Fletcher JG, Nathan MA, et al. Time interval between abnormalities seen on CT and the clinical diagnosis of pancreatic cancer: retrospective review of CT scans obtained before diagnosis. AJR Am J Roentgenol. 2004;182(4):897-903. (Pubitemid 38391649)
97. Permert J, Larsson J, Westermark GT, et al. Islet amyloid polypeptide in patients with pancreatic cancer and diabetes. N Engl J Med. 1994;330(5):313-318. (Pubitemid 24041375)
98. Permert J, Larsson J, Fruin AB, et al. Islet hormone secretion in pancreatic cancer patients with diabetes. Pancreas. 1997;15(1):60-68. (Pubitemid 27527361)
99. Permert J, Herrington M, Kazakoff K, et al. Early changes in islet hormone secretion in the hamster pancreatic cancer model. Teratogenesis, Carcinogenesis, and Mutagenesis. 2001;21(1):59-67.
100. Katsumichi I, Pour PM. Diabetes mellitus in pancreatic cancer: is it a causal relationship?. Am J Surg. 2007;194(suppl 4):S71-S75. (Pubitemid 47445397)
101. Chari ST, Klee GG, Miller LJ, et al. Islet amyloid polypeptide is not a satisfactory marker for detecting pancreatic cancer. Gastroenterology. 2001;121(3):640-645. (Pubitemid 32822579)
102. Basso D, Millino C, Greco E, et al. Altered glucose metabolism and proteolysis in pancreatic cancer cell conditioned myoblasts: searching for a gene expression pattern with a microarray analysis of 5000 skeletal muscle genes. Gut. 2004;53(8):1159-1166. (Pubitemid 38961972)
103. Basso D, Greco E, Fogar P, et al. Pancreatic cancer-derived S-100A8 N-terminal peptide: a diabetes cause? Clin Chim Acta. 2006;372(1-2):120-128.
104. Jones S, Hruban RH, Kamiyama M, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science. 2009;324(5924):217.
105. Ahren B, Andren-Sandberg A. Glucose tolerance and insulin secretion in experimental pancreatic cancer in the Syrian hamster. Res Exp Med (Berl). 1993;193(1):21-26. (Pubitemid 23062490)
106. Liu J, Knezetic JA, Strommer L, et al. The intracellular mechanism of insulin resistance in pancreatic cancer patients. J Clin Endocrinol Metab. 2000;85(3):1232-1238. (Pubitemid 32269378)
107. Ding X, Flatt PR, Permert J, et al. Pancreatic cancer cells selectively stimulate islet beta cells to secrete amylin. Gastroenterology. 1998;114(1):130-138. (Pubitemid 28020963)
108. Permert J, Ihse I, Jorfeldt L, et al. Improved glucose metabolism after subtotal pancreatectomy for pancreatic cancer. Br J Surg. 1993;80(8):1047-1050. (Pubitemid 23261595)
109. Fogar P, Pasquali C, Basso D, et al. Diabetes mellitus in pancreatic cancer follow-up. Anticancer Res. 1994;14(6B):2827-2830.
110. Grote VA, Becker S, Kaaks R. Diabetes mellitus type 2 - an independent risk factor for cancer? Exp Clin Endocrinol Diabetes. 2010;118(1):4-8.
111. Cersosimo E, Pisters PW, Pesola G, et al. Insulin secretion and action in patients with pancreatic cancer. Cancer. 1991;67(2):486-493.
112. Permert J, Ihse I, Jorfeldt L, et al. Pancreatic cancer is associated with impaired glucose metabolism. Eur J Surg. 1993;159(2):101-107. (Pubitemid 23112386)
113. Centers for Disease Control. National Diabetes Fact Sheet, 2007. Available at: http://www.cdc.gov/diabetes/pubs/pdf/ndfs-2007.pdf. Updated 2007. Accessed January 26, 2010.
114. Slezak LA, Andersen DK. Pancreatic resection: effects on glucose metabolism. World J Surg. 2001;25(4):452-460. (Pubitemid 32455198)
115. Seymour NE, Andersen DK. Pancreatic polypeptide and glucose metabolism. In: Greeley GH, ed. Gastrointestinal Endocrinology. Totowa, NJ: Humana Press; 1999:321-334.
116. Andersen DK. Mechanisms and emerging treatments of the metabolic complications of chronic pancreatitis. Pancreas. 2007;35(1):1-15. (Pubitemid 46956195)
117. Goldstein JA, Kirwin JD, Seymour NE, et al. Reversal of in vitro hepatic insulin resistance in chronic pancreatitis by pancreatic polypeptide in the rat. Surgery. 1989;106(6):1128-1132; discussion, 1132-1133.
118. Seymour NE, Volpert AR, Lee EL, et al. Alterations in hepatocyte insulin binding in chronic pancreatitis: effects of pancreatic polypeptide. Am J Surg. 1995;169(1):105-109; discussion, 110.
119. Sun YS, Brunicardi FC, Druck P, et al. Reversal of abnormal glucose metabolism in chronic pancreatitis by administration of pancreatic polypeptide. Am J Surg. 1986;151(1):130-140. (Pubitemid 16143194)
120. Prillaman HM, Cox SB, Freedlender AE, et al. The effect of pancreatic polypeptide on glucose disposal after surgical alterations of the pancreas. Ann Surg. 1992;216(5):574-582.
121. Seymour NE, Brunicardi FC, Chaiken RL, et al. Reversal of abnormal glucose production after pancreatic resection by pancreatic polypeptide administration in man. Surgery. 1988;104(2):119-129.
122. Brunicardi FC, Chaiken RL, Ryan AS, et al. Pancreatic polypeptide administration improves abnormal glucose metabolism in patients with chronic pancreatitis. J Clin Endocrinol Metab. 1996;81(10):3566-3572. (Pubitemid 26339916)